Serotonin 5-HT2B Antagonists Avoiding hERG Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myxomatous mitral valve disease (MMVD) and congestive heart failure (CHF) in animals, such as angiotensin enzyme inhibitors and diuretics, provide only symptomatic relief and pose adverse risks, while existing serotonin 5-HT2B receptor antagonists often inhibit the hERG potassium channel, leading to cardiac risks.
Innovation Solution
Development of novel serotonin 5-HT2B receptor antagonists with minimal affinity for the hERG potassium channel, specifically compounds like (4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone, which are designed to treat MMVD and CHF in animals without the cardiac risks associated with hERG inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing serotonin 5-HT2B receptor antagonists are used to treat MMVD and CHF, then serotonin signaling is blocked to prevent valve damage and cardiac hypertrophy, but hERG potassium channel inhibition occurs leading to cardiac arrhythmia risks
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity - high affinity for 5-HT2B receptor (to achieve therapeutic effect) and low affinity for hERG channel (to avoid harmful effect). The molecular structure is optimized to create different interaction properties with different protein targets, allowing beneficial action at the 5-HT2B site while avoiding harmful action at the hERG site.
Solution Approach 2:
The patent employs parameter changes by modifying molecular structure parameters (substituents on the core heterocyclic ring, chain length, functional groups) to tune the balance between 5-HT2B antagonism and hERG inhibition. By changing structural parameters, the compound achieves optimal therapeutic window with sufficient 5-HT2B blocking activity and minimal hERG channel blocking activity.
2Ease of operation
If current treatments for MMVD (angiotensin enzyme inhibitors, diuretics) are used, then symptomatic relief is provided, but adverse risks increase including loss of appetite, lethargy, and renal damage
Solution Approach 1:
The patent extracts the harmful side effects from the treatment by using a completely different mechanism of action (5-HT2B antagonism) compared to conventional treatments (ACE inhibition, diuresis). This extracts the therapeutic benefit of symptom management while eliminating the specific adverse effects associated with conventional drug classes, such as renal damage from diuretics and appetite suppression from ACE inhibitors.
3Duration of action of moving object
If 5-HT2B receptor antagonists with high affinity are developed, then disease progression is slowed, but cardiac safety is compromised due to hERG inhibition
Solution Approach 1:
The patent applies preliminary action by conducting in silico and in vitro screening to predict and evaluate hERG inhibition risk before clinical development. Computational models and binding assays are performed in advance to identify compounds with favorable safety profiles, preventing progression of compounds with high hERG inhibition risk into clinical trials.
Data Source
AI summary
The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in animals, preferably canine.